ptc299
Small moleculeexperimental
Clinical trial activity
7 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00508586)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole
- ptc299
- ptc299
- ptc299
- ptc299
- skf86002
- sk&f 86002
- skf 86002
- sk&f 86002-a(2)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04439071 | Phase 2/Phase 3 (Phase 3) | Jun 30, 2020 | PTC Therapeutics |
| NCT03761069 | Phase 1 | Oct 29, 2018 | PTC Therapeutics |
| NCT01158300 | Phase 1 | Nov 1, 2010 | Children's National Medical Center, National Cancer Institute (NCI), Pediatric Brain Tumor Consortium, PTC Therapeutics |
| NCT00911248 | Phase 2 | Jul 1, 2009 | Department of Defense, PTC Therapeutics |
| NCT00686842 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2008 | AIDS Malignancy Consortium, Cornell University, National Cancer Institute (NCI), PTC Therapeutics, The EMMES Corporation |
| NCT00704821 | Phase 1 | Jun 1, 2008 | Cornell University, PTC Therapeutics |
| NCT00508586 | Phase 1 | Nov 1, 2007 | Department of Defense, PTC Therapeutics |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PTC Therapeutics | For profit | 7 | 5 | 3 | 2007 |
| Cornell University | Academic/Hospital | 2 | 0 | 2 | 2008 |
| Department of Defense | Government | 2 | 0 | 2 | 2007 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2008 |
| AIDS Malignancy Consortium | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Children's National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Pediatric Brain Tumor Consortium | Academic/Hospital | 1 | 1 | 1 | 2010 |
| The EMMES Corporation | For profit | 1 | 0 | 1 | 2008 |
8 organizations
Page 1 / 1